{
    "clinical_study": {
        "@rank": "105828", 
        "acronym": "EFFIPAP", 
        "arm_group": [
            {
                "arm_group_label": "Historical control arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients transfused with platelet concentrates re-suspended in autologous plasma"
            }, 
            {
                "arm_group_label": "Control arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients transfused with platelets prepared in additive solution"
            }, 
            {
                "arm_group_label": "Experimental arm", 
                "arm_group_type": "Experimental", 
                "description": "Patients transfused with platelets treated by pathogen reduction process"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multicentre, double-blind, randomized therapeutic trial.\n\n      The primary objective of this study is to evaluate non-inferiority with regard to prevention\n      and control of haemorrhage:\n\n        -  of platelet concentrates treated by pathogen reduction(Intercept  amotosalen and UVA\n           procedure)\n\n        -  compared with the usual platelet concentrates (in additive solution intersol),\n           reference arm, and\n\n        -  compared with platelet concentrates re-suspended in autologous plasma (historic arm)\n           These three products are available and authorised by ANSM (formerly AFSSAPS).\n\n      The secondary objectives is to evaluate the transfusion needs, transfusion outcomes and\n      safety and the decreased frequency of grade 2 or higher side effects related to transfusion\n      allergy to platelets."
        }, 
        "brief_title": "Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Aplasia With Expected Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "There is an unresolved difficulty in the evaluation of haemorrhagic symptoms in\n      thrombocytopenia due to the very nature of the scale, which is the international standard at\n      this time (WHO scale). This scale is based on the level of blood loss and is applicable to\n      any haemostasis disorder. We will keep it as the standard but have decided to be\n      particularly rigorous in the data collection and will perform daily haemorrhagic assessment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 18 years or older\n\n          -  Patient hospitalised for bone marrow aplasia, with expected stay of over 10 days and\n             in principle requiring platelet transfusion support (at least twice).\n\n          -  Signed informed consent\n\n          -  Patients with DIC can be included; they will undergo a separate analysis.\n\n          -  A negative pregnancy test is necessary before inclusion in all women of childbearing\n             age\n\n        Exclusion Criteria:\n\n          -  Patient included in this trial previously during a prior aplasia episode.\n\n          -  Patient requiring curative anticoagulant treatment at the time of inclusion (vitamin\n             K antagonists, heparin (LMWH and NFH), anti-IIa and Xa at curative doses for\n             treatment or prophylaxis of arterial or venous thromboembolic disease (TED) or as\n             part of the treatment for cardiac valvulopathy and complications of atrial\n             fibrillation).\n\n          -  Thrombocytopenia due to increased destruction\n\n          -  Patient requires washed platelet concentrates (i.e., with residual plasma less than\n             that remaining during the addition of an additive solution) due to previous\n             intolerance to platelets (cf IgA deficiency, history of major allergic reaction)\n\n          -  Patient requiring products \"CMV negative \" (previously included in a protocol\n             transfusion CMV negative)\n\n          -  Patients with platelet transfusion refractoriness during a previous period of\n             cytopenia, including patient with platelet refractoriness related to an anti-HLA\n             alloimmunization (thus, patient already known as requiring compatible platelets HLA)\n\n          -  Patient who requires compatible HLA platelets due to a refractory state relative to\n             anti-HLA alloimmunization\n\n          -  Patient presenting a platelet transfusion refractoriness at the time of previous\n             aplasia.\n\n          -  Protected adults and persons deprived of liberty"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "810", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789762", 
            "org_study_id": "2012-P001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Historical control arm", 
                "description": "Transfusions of platelet concentrates re-suspended in autologous plasma", 
                "intervention_name": "Autologous plasma", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Control arm", 
                "description": "Transfusions of platelets prepared in additive solution (Intersol)", 
                "intervention_name": "Additive solution", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Experimental arm", 
                "description": "Patients transfused with platelets treated by pathogen reduction process", 
                "intervention_name": "Pathogen reduction process", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Platelet transfusions", 
            "Pathogen reduction", 
            "Haemorrhagic episodes"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Besancon", 
                        "country": "France", 
                        "zip": "25030"
                    }, 
                    "name": "CHU de Besancon"
                }, 
                "investigator": {
                    "last_name": "Eric Deconinck, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "catherine.leniger@chu-brest.fr", 
                    "last_name": "Catherine Le Niger, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France"
                    }, 
                    "name": "CHU de Brest"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France", 
                        "zip": "63003"
                    }, 
                    "name": "CHU de Clermont Ferrand"
                }, 
                "investigator": {
                    "last_name": "Jacques-Olivier Bay, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94000"
                    }, 
                    "name": "CHU Henri Mondor - APHP"
                }, 
                "investigator": {
                    "last_name": "Catherine Cordonnier, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21000"
                    }, 
                    "name": "CHU de Dijon"
                }, 
                "investigator": {
                    "last_name": "Denis Caillot, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "frederic.garban@efs.sante.fr", 
                    "last_name": "Frederic Garban, MD, PhD", 
                    "phone": "+33 (0) 4 76 42 43 44"
                }, 
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "zip": "38700"
                    }, 
                    "name": "CHU de Grenoble"
                }, 
                "investigator": {
                    "last_name": "Frederic Garban, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }, 
                    "name": "Institut Paoli Calmette"
                }, 
                "investigator": {
                    "last_name": "Patrick Ladaique, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "simona.lapusan@sat.aphp.fr", 
                    "last_name": "Simona Lapusan, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75012"
                    }, 
                    "name": "Hopital Saint Antoine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre Benite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Hospices Civils de Lyon - Lyon Sud"
                }, 
                "investigator": {
                    "last_name": "H\u00e9l\u00e8ne Labussi\u00e8re, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU de Rennes"
                }, 
                "investigator": {
                    "last_name": "Stanislas Nimubona, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Priest en Jarez", 
                        "country": "France", 
                        "zip": "42271"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de la Loire"
                }, 
                "investigator": {
                    "last_name": "Christine Mounier, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process", 
        "overall_contact": {
            "email": "pierre.tiberghien@efs.sante.fr", 
            "last_name": "Pierre Tiberghien, MD, PhD", 
            "phone": "+33 (0) 1 55 93 95 90"
        }, 
        "overall_contact_backup": {
            "email": "frederic.garban@efs.sante.fr", 
            "last_name": "Frederic Garban, MD, PhD", 
            "phone": "+33 (0) 4 76 42 43 44"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: French Data Protection Authority"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of grade 2 or higher (WHO) haemorrhagic episodes", 
            "safety_issue": "Yes", 
            "time_frame": "During 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency incidence of haemorrhagic episodes  (grade 1 and higher)", 
                "safety_issue": "Yes", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Number of serious grade 3-4 haemorrhagic episodes", 
                "safety_issue": "Yes", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Number of minor grade 1 haemorrhagic episodes", 
                "safety_issue": "Yes", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Transfusion outcome in platelets (CCI) at 24 hours", 
                "safety_issue": "No", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Number of transfusions of platelet concentrates and red blood cells", 
                "safety_issue": "No", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Transfusion intervals", 
                "safety_issue": "No", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Safety (transfusion side effects) grade 2 or higher", 
                "safety_issue": "Yes", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Occurrence of anti-platelet antibodies (Anti-HLA, anti-HPA)", 
                "safety_issue": "No", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Occurrence of platelet transfusions refractiveness", 
                "safety_issue": "Yes", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Validation of a new haemorrhagic evaluation: EFS scale", 
                "safety_issue": "No", 
                "time_frame": "During 1 month"
            }, 
            {
                "measure": "Variation  in hematocrit and hemoglobin levels", 
                "safety_issue": "Yes", 
                "time_frame": "During 1 month"
            }
        ], 
        "source": "Etablissement Fran\u00e7ais du Sang", 
        "sponsors": {
            "collaborator": {
                "agency": "Centre Investigation Clinique - Hospital of Grenoble", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Etablissement Fran\u00e7ais du Sang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}